Biogen Earnings: New Drug Sparks Life
Biogen (NASDAQ:BIIB) reported first-quarter earnings on Tuesday, resulting in investors excited about the potential for Spinraza, its new spinal muscular atrophy drug developed with Ionis Pharmaceuticals (NASDAQ:IONS), but tolerating ho-hum sales growth of its multiple sclerosis drugs.
What happened with Biogen this quarter?
The quarterly results look worse than they really are because this quarter doesn't include its hemophilia drugs that were spun out into Bioverativ (NASDAQ:BIVV) in mid-January. Excluding those sales from both quarters, revenue was up a solid-albeit-not-outstanding 8%.
What happened with Biogen this quarter?
The quarterly results look worse than they really are because this quarter doesn't include its hemophilia drugs that were spun out into Bioverativ (NASDAQ:BIVV) in mid-January. Excluding those sales from both quarters, revenue was up a solid-albeit-not-outstanding 8%.